Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis

Ando, Kenji; Tobino, Kazunori; Kurihara, Masatoshi; Kataoka, Hideyuki; Doi, Takehiko; Hoshika, Yoshito; Takahashi, Kazuhisa; Seyama, Kuniaki

doi:10.1016/j.ejrad.2012.05.033

Cited by 12 publications

(9 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Taveira-DaSilva et al reported that the estimated SPAP on echocardiography > 35 mmHg was observed in less than 10% of 95 LAM patients [ 20 ], but FEV 1 %predicted and PaO 2 in their subjects were 71.4% and 78.4 Torr, respectively, values that were much milder than those in our population (32.8% and 55.7 Torr, respectively). Our previous quantitative CT analysis demonstrated that cystic lung destruction did not necessarily accompany a concomitant loss of pulmonary vasculature in LAM [ 21 ]. Overall, it would be fair to say that PH is prevalent in less than 20% of LAM patients at their registration for lung transplantation.…”

Section: Discussionmentioning

confidence: 99%

Lung Transplantation for Lymphangioleiomyomatosis in Japan

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundLung transplantation has been established as the definitive treatment option for patients with advanced lymphangioleiomyomatosis (LAM). However, the prognosis after registration and the circumstances of lung transplantation with sirolimus therapy have never been reported.MethodsIn this national survey, we analyzed data from 98 LAM patients registered for lung transplantation in the Japan Organ Transplantation Network.ResultsTransplantation was performed in 57 patients as of March 2014. Survival rate was 86.7% at 1 year, 82.5% at 3 years, 73.7% at 5 years, and 73.7% at 10 years. Of the 98 patients, 21 had an inactive status and received sirolimus more frequently than those with an active history (67% vs. 5%, p<0.001). Nine of twelve patients who remained inactive as of March 2014 initiated sirolimus before or while on a waiting list, and remained on sirolimus thereafter. Although the statistical analysis showed no statistically significant difference, the survival rate after registration tended to be better for lung transplant recipients than for those who awaited transplantation (p = 0.053).ConclusionsLung transplantation is a satisfactory therapeutic option for advanced LAM, but the circumstances for pre-transplantation LAM patients are likely to alter with the use of sirolimus.

show abstract

Section: Discussionmentioning

confidence: 99%

Lung Transplantation for Lymphangioleiomyomatosis in Japan

et al. 2016

Self Cite

View full text Add to dashboard Cite

show abstract

“…Quantitative imaging might detect early changes, often underestimated [19,20]. This emerging radiological technique could provide clinicians with a reliable tool to estimate both parenchymal lung involvement and degree of airflow impairment [77,78], similarly to histology and functional tests, respectively. Scientific community, however, is still evaluating risks associated with repeated exposures to high ionizing radiation doses [79] (increased lifetime radiation attributable risk of cancer).…”

Section: Discussionmentioning

confidence: 99%

Role of thoracic imaging in the management of lymphangioleiomyomatosis

Crivelli

Ledda

Terraneo

et al. 2019

Respiratory Medicine

View full text Add to dashboard Cite

Lymphangioleiomyomatosis (LAM) is a rare diffuse lung cystic disease (DLCD) that occurs sporadically or in association with Tuberous Sclerosis Complex (TSC). The diagnostic pathway is tracked on the identification of the disease hallmarks on chest High-Resolution Computed Tomography (HRCT).Aim of this review is to discuss the thoracic HRCT pathognomonic features, essential to rule out other DLCD. It also examines the new evidences emerging from Computed Tomography (CT) quantitative studies that, by demonstrating a specific cysts distribution and a pathological aspect of the parenchyma near the cysts, could improve our understanding of this rare disorder and supply pulmonologists with a new tool for a more appropriate long-term management. Finally, the contribution of other image techniques as low dose chest CT, Magnetic Resonance Imaging (MRI) and Ultrasound (US) is discussed.

show abstract

“…This contrast reveals that although patients with PLAM have cystic changes, these changes did not result in significant variations in the LV. Prior studies have compared PLAM patients with COPD patients and found that under the same pulmonary function measured by PFTs, quantitative HRCT showed that the areas of parenchymal destruction in PLAM patients were relatively less severe than those of COPD patients and that the percentage of pulmonary small blood vessels and mean area of the lung parenchyma were higher in PLAM patients than in COPD patients (10).…”

Section: Plam Mainly Reveals Itself Through Diffuse Cystic Changesmentioning

confidence: 98%

Quantitative assessment of pulmonary function in lymphangioleiomyomatosis patients using high-resolution computed tomography and pulmonary function tests

Liu

et al. 2020

J Thorac Dis

View full text Add to dashboard Cite

Background: To explore the feasibility of using quantitative high-resolution computed tomography (HRCT) to evaluate pulmonary function in patients with pulmonary lymphangioleiomyomatosis (PLAM). Methods: Pulmonary function tests (PFTs) were performed in 30 patients with pathologically confirmed PLAM with the use of HRCT. These results were correlated with quantitative HRCT in 21 patients. Results: There were significant correlations between the HRCT parameters for lung function and PFT parameters. Among these parameters, emphysema volume (EV), pulmonary volume with a pixel index less than the trigger threshold (−950 HU) to account for a proportion of total lung volume [PI-950 (%)] and forced expiratory volume in 1 second/forced vital capacity [FEV1/FVC (%)] had the strongest correlations, reaching values between −0.71 and −0.68. HRCT lung function might therefore also be helpful for predicting changes in lung function before and after treatment. Conclusions: HRCT is helpful for the assessment of pulmonary function in PLAM patients and can assist in the clinical evaluation of lung function and treatment response in patients with this disease.

show abstract

Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis

Cited by 12 publications

References 16 publications

Lung Transplantation for Lymphangioleiomyomatosis in Japan

Lung Transplantation for Lymphangioleiomyomatosis in Japan

Role of thoracic imaging in the management of lymphangioleiomyomatosis

Quantitative assessment of pulmonary function in lymphangioleiomyomatosis patients using high-resolution computed tomography and pulmonary function tests

Contact Info

Product

Resources

About